Antitumor Effect of Bevacizumab in a Xenograft Model of Canine Hemangiopericytoma

Journal of Pharmacological Sciences

Tatsuya Uto²  Ryota Nakazawa²  Daigo Azakami¹  Tsuyoshi Tajima⁵  Hisashi Yoshimura²  Yuko Naya³  Kikumi Ogihara³  Masaki Michishita²  Seigo Kishikawa³  Kimimasa Takahashi²  Toshiro Arai⁴ 

[1] Department of Veterinary Nursing, Nippon Veterinary and Life Science University, Japan;Department of Veterinary Pathology, Nippon Veterinary and Life Science University, Japan;Department of Pathology, School of Life and Environmental Science, Azabu University, Japan;Department of Veterinary Biochemistry, Nippon Veterinary and Life Science University, Japan;Department of Veterinary Pharmacology, Nippon Veterinary and Life Science University, Japan

关键词: bevacizumab;    canine hemangiopericytoma;    vascular endothelial growth factor (VEGF);   

DOI  :  10.1254/jphs.12268SC

学科分类：药学

来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society

【 摘 要 】

References(15)Cited-By(5)Canine hemangiopericytoma (CHP) is characterized by frequent local recurrence and increased invasiveness. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis in tumors. The aim of the present study was to investigate the effect of a single dose of bevacizumab on a xenograft model of CHP. VEGF protein was secreted from cultured CHP cells and interacted with bevacizumab. Bevacizumab treatment suppressed tumor growth by inhibiting tumor angiogenesis, whereas no significant differences were observed in the proliferation index and apoptosis rates of treated and untreated mice. Thus, bevacizumab had antitumor effects in a xenograft model of CHP.

【 授权许可】

Unknown